Literature DB >> 7695334

Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.

A Rosowsky1, J B Hynes, S F Queener.   

Abstract

Twenty-eight 2,4-diaminopteridines with alkyl and aralkyl groups at the 6- and 7-positions, five 1,3-diamino-7,8,9,10-tetrahydropyrimido [4,5-c]isoquinolines with an alkyl, alkylthio, or aryl group at the 6-position, and nine 4,6-diamino-1,2-dihydro-s-triazines with one or two alkyl groups at the 2-position and a substituted phenyl or naphthyl group at the 1-position were evaluated as inhibitors of dihydrofolate reductase enzymes from Pneumocystis carinii, Toxoplasma gondii, and rat liver. Halogen substitution at the 5- or 6-position of 2,4-diaminoquinazoline favored selective binding to the P. carinii enzyme but not the T. gondii enzyme. For example, the 50% inhibitory concentrations of 2,4-diamino-6-chloroquinazoline as an inhibitor of P. carinii, T. gondii, and rat liver dihydrofolate reductase were 3.6, 14 and 29 microM, respectively, corresponding to 12-fold selectivity for the P. carinii enzyme but only marginal selectivity for the T. gondii enzyme. Greater than fivefold selectivity for P. carinii but not T. gondii dihydrofolate reductase was also observed for the 2,4-diaminoquinazolines with 5-methyl, 5-fluoro, 5- and 6-bromo, 6-chloro, and 5-chloro-6-bromo substitution. In contrast, alkyl and aralkyl substitution at the 6- and 7-positions of 2,4-diaminopteridines was found to be a favorable feature for selective inhibition of the T. gondii enzyme and, in two cases, for both enzymes. Nine of the fifty-one compounds tested against P. carinii dihydrofolate reductase and four of the thirty compounds tested against T. gondii dihydrofolate reductase displayed fivefold or greater selectivity for the microbial enzyme versus the rat liver enzyme. The most selective against both enzymes was 2,4-diamino-6,7-bis(cyclohexylmethyl) pteridine, with a selectivity ratio 2 orders of magnitude greater than the value reported for trimetrexate and piritrexim. Since substitution at the 7-position is generally considered to be detrimental to the binding of 2,4-diaminop-teridines and related compounds to mammalian dihydrofolate reductase, the selectivity observed in this study with the 6,7-bis(cyclohexylmethyl) analog may represent a useful approach to enhancing selective inhibition of the enzyme from nonmammalian species.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695334      PMCID: PMC162489          DOI: 10.1128/AAC.39.1.79

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

Authors:  S F Queener; M S Bartlett; M A Jay; M M Durkin; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.

Authors:  M C Broughton; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

3.  Susceptibility of Pneumocystis carinii to artemisinin in vitro.

Authors:  S Merali; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.

Authors:  B Ruf; D Schürmann; F Bergmann; W Schüler-Maué; T Grünewald; H J Gottschalk; H Witt; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

6.  Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

7.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  W Hughes; G Leoung; F Kramer; S A Bozzette; S Safrin; P Frame; N Clumeck; H Masur; D Lancaster; C Chan
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

8.  Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species.

Authors:  D M Schmatz; G Abruzzo; M A Powles; D C McFadden; J M Balkovec; R M Black; K Nollstadt; K Bartizal
Journal:  J Antibiot (Tokyo)       Date:  1992-12       Impact factor: 2.649

9.  Suppressive effect of deferoxamine on the growth of Pneumocystis carinii in vitro.

Authors:  G A Weinberg; M M Shaw
Journal:  J Protozool       Date:  1991 Nov-Dec

10.  Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS.

Authors:  H Masur; M A Polis; C U Tuazon; D Ogata-Arakaki; J A Kovacs; D Katz; D Hilt; T Simmons; I Feuerstein; B Lundgren
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

View more
  11 in total

Review 1.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

2.  6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.

Authors:  H C Jackson; K Biggadike; E McKilligin; O S Kinsman; S F Queener; A Lane; J E Smith
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.

Authors:  V H Brophy; J Vasquez; R G Nelson; J R Forney; A Rosowsky; C H Sibley
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.

Authors:  R G Nelson; A Rosowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.

Authors:  Bharath Srinivasan; Sam Tonddast-Navaei; Jeffrey Skolnick
Journal:  Eur J Med Chem       Date:  2015-09-05       Impact factor: 6.514

7.  Rational Design of Novel Allosteric Dihydrofolate Reductase Inhibitors Showing Antibacterial Effects on Drug-Resistant Escherichia coli Escape Variants.

Authors:  Bharath Srinivasan; João V Rodrigues; Sam Tonddast-Navaei; Eugene Shakhnovich; Jeffrey Skolnick
Journal:  ACS Chem Biol       Date:  2017-05-31       Impact factor: 5.100

8.  High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.

Authors:  Anuradha Kumar; Meng Zhang; Linyun Zhu; Reiling P Liao; Charles Mutai; Shittu Hafsat; David R Sherman; Ming-Wei Wang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

10.  2D depiction of fragment hierarchies.

Authors:  Alex M Clark
Journal:  J Chem Inf Model       Date:  2010-01       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.